-
s
- Salvage therapy
Second-line therapy; used to treat disease that has not responded to initial therapy or relapsed disease.
- Serum protein electrophoresis (SPEP)
Test used to measure the levels of various proteins in the blood or serum. Uses an electrical current to sort proteins by their charge and size.
- Smoldering multiple myeloma (SMM)
Type of asymptomatic myeloma representing about 5% of cases and noted by monoclonal protein and slightly increased numbers of plasma cells in the bone marrow. Patients with SMM are monitored and currently only treated if their disease progresses.
- Special Protocol Assessment (SPA)
Procedure by which the U.S. Food and Drug Administration (FDA) evaluates and provides guidance on proposed protocols for pivotal Phase III clinical trials. The SPA provides the trial sponsors with a binding written agreement that the design and analysis of the study are adequate to support an(...) - Stable disease (SD)
Treatment outcome where the disease has not responded to therapy but has not progressed. It also refers to disease that initially responded to therapy and remains stable after treatment is stopped.
- Stage I disease
Myeloma disease classification based on the Revised International Staging System (R-ISS). Patients with Stage I disease have: ß2-M less than or equal to 3.5mg/L and albumin greater than or equal to 3.5 g/dL, Absence of higher-risk DNA [deletion(17p) and/or translocation t(4;14) and/or(...) - Stage II disease
Myeloma disease classification based on the Revised International Staging System (R-ISS). Patients with Stage II disease have: Neither Stage I nor Stage III disease
- Stage III disease
Myeloma disease classification based on the Revised International Staging System (R-ISS) Patients with Stage III disease have: ß2-M greater than or equal to 5.5mg/L and either , Presence of higher-risk DNA abnormalities [deletion(17p) and/or translocation t(4;14) and/or translocation(...) - Standard-dose chemotherapy
Administration of chemotherapy at a dose that does not completely destroy the bone marrow; also known asAdministration of chemotherapy at a dose that does not completely destroy the bone marrow; also known as conventional chemotherapy.conventional chemotherapy.
- Standard of care
Treatment that experts agree is appropriate, accepted and widely used; also called standard therapy or best practice.
- Standard risk disease
Indicates myeloma with an average prognosis.
- Standard therapy
Treatment that has been shown to be safe and effective in clinical studies and is adopted as standard practice outside of clinical trials.
- Stem cell
Parent cell that grows and divides to produce red blood cells, white blood cells and platelets. Found primarily in the bone marrow, but also in the peripheral blood.
- Stem cell transplant
Therapeutic procedure in which bone marrow or peripheral blood stem cells are collected, stored and infused into a patient following high-dose chemotherapy to restore blood cell production.
- Stevens-Johnson syndrome
A rare, but very serious type of rash, resulting from an allergic reaction. It has been rarely documented in patients who received Revlimid. It requires immediate medical attention.
- Stomatitis
Mouth sores.
- Stringent complete response
A treatment outcome where there are no detectable plasma cells in the bone marrow or myeloma proteins in the serum or urine using very sensitive techniques. A test known as free light chain ratio is also normal.
- Stromal cell
Structural cells of the bone marrow that help support and nourish the blood-producing cells.
- Supplemental New Drug Application (sNDA)
Compilation of information on the safety and efficacy of a marketed drug that is submitted to the FDA in order to request approval to market the drug for another indication.
- Supportive care
Treatment that addresses the symptoms and complications of a disease rather than the disease itself. Examples in myeloma include bisphosphonates, growth factors (i.e., erythropoietin), antibiotics, orthopedic interventions and pain control measures.
- Synergistic
Acts in combination with another agent such that the activity is greater than the simple additive effect of the two agents.
- Syngeneic stem cell transplant
Procedure in which bone marrow or peripheral blood stem cells from a patient’s identical twin are collected, stored and infused into the patient following high-dose chemotherapy or radiation therapy.
This site uses cookies and other tracking technologies to assist with navigation and your ability to provide feedback, analyze your use of our products and services, assist with our promotional and marketing efforts, and provide content from third parties.
Need help? Chat now
The information provided by our AI chatbot is for general informational purposes only and
does not constitute medical advice. For any health-related questions, you should seek
professional medical advice.
By using our AI chatbot, you agree to let us store your messages.
For further details, see our privacy policy.
The Patient Navigation Center team can provide further detailed information. They're available at 1-888-841-6673, Monday-Friday, 9 AM-7 PM ET. You can also use the PNC contact web form.